Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation
Hudson G, Schaefer AM, Taylor RW, Tiangyou W, Gibson A, Venables G, Griffiths P, Burn DJ, Turnbull DM, Chinnery PF (2007) Mutation of the linker region of the polymerase gamma-1 (POLG1) gene associated with progressive external ophthalmoplegia and parkinsonism
KPVs strongest preclinical evidence is for oral delivery to gut tissue, where inflamed intestinal cells actively absorb it via the PepT1 transporter (upregulated during inflammation)
The 5% concentration, approved for men, demonstrates more significant clinical benefits than the 2% solution commonly recommended for women
Visible Results in Just Days Customers report brighter, more even skin in as little as 35 days of consistent use
The most frequently noted adverse effects in user reports are mild digestive disturbances when taken orally and injection site reactions
